Retatrutide vs Tirzepatide vs Semaglutide: The Triple-Agonist Era
TL;DR
Three peptides now dominate the conversation around medically-supervised weight loss: semaglutide (Ozempic / Wegovy), tirzepatide (Mounjaro / Zepbound), and the investigational retatrutide (LY3437943). They differ in how many receptors they hit, how much weight they produce, and how available they are. In clinical trials, semaglutide delivers ~15% body weight reduction, tirzepatide ~22%, and retatrutide ~24% — but only the first two are FDA-approved as of 2026. This guide explains what's actually different about each molecule and how to think about the choice.
The Three Drugs at a Glance
| | Semaglutide | Tirzepatide | Retatrutide | |---|---|---|---| | Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound | LY3437943 (none yet) | | Maker | Novo Nordisk | Eli Lilly | Eli Lilly | | Receptors targeted | GLP-1 (single agonist) | GLP-1 + GIP (dual agonist) | GLP-1 + GIP + glucagon (triple agonist) | | FDA status | Approved (T2D + weight) | Approved (T2D + weight) | Phase 3, not approved | | Peak weight loss (trial) | 15–17% at 68 weeks | 20–22.5% at 72 weeks | 24.2% at 48 weeks | | Dosing | 0.25 → 2.4 mg/wk | 2.5 → 15 mg/wk | 2 → 12 mg/wk (investigational) | | Access today | Prescription, compounded | Prescription, compounded | Research-chemical channels only |
These numbers come from the STEP trials (semaglutide), SURMOUNT trials (tirzepatide), and TRIUMPH-1 (retatrutide Phase 2). All three were placebo-controlled, randomized, in non-diabetic adults with overweight or obesity.
Mechanism: The Difference Is Which Hormones They Mimic
Your gut releases hormones after meals that tell your pancreas to release insulin, slow your stomach down, and signal "I'm full" to your brain. Drug developers have figured out how to make synthetic peptides that mimic these hormones at much higher doses than your body would ever produce naturally. The three drugs differ in how many of these signals they hijack.
Semaglutide — GLP-1 only
GLP-1 (glucagon-like peptide-1) is the most studied incretin hormone. It slows gastric emptying so food stays in your stomach longer, suppresses appetite via the hypothalamus, and stimulates insulin secretion in a glucose-dependent way (so it doesn't cause low blood sugar in non-diabetics). Semaglutide is a GLP-1 mimic with a much longer half-life than the natural hormone — one weekly injection is enough.
Tirzepatide — GLP-1 + GIP
Tirzepatide adds activation of the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP's role in weight management is less clear-cut, but its addition appears to enhance insulin sensitivity, reduce glucagon secretion, and possibly directly modulate fat-cell metabolism. Whatever the exact mechanism, the dual-agonist approach in head-to-head trials consistently outperforms GLP-1 alone.
Retatrutide — GLP-1 + GIP + glucagon
Retatrutide is the first triple agonist to reach late-stage trials. Adding glucagon receptor agonism is the genuinely novel part: where GLP-1 and GIP both reduce calorie intake (less appetite, slower digestion), glucagon agonism increases calorie output. Specifically, it raises basal metabolic rate by 3–5% and stimulates hepatic lipolysis (the liver burning its own fat stores). For the first time, a single drug both eats less and burns more.
That's the mechanistic reason retatrutide produced larger weight losses in Phase 2 than any prior GLP-1-class drug.
Clinical Results: What the Trials Actually Showed
Semaglutide — STEP trial program
STEP-1 (2021): 1,961 participants without diabetes, BMI ≥30 or ≥27 with weight-related comorbidity. Mean weight reduction: 14.9% on semaglutide 2.4 mg vs 2.4% on placebo at 68 weeks. 86% achieved ≥5% weight loss; 50% achieved ≥15%. The SELECT trial (2023) additionally showed a 20% reduction in major adverse cardiovascular events in obese adults with established CVD — moving semaglutide from a "weight loss drug" to a "cardiovascular drug that also reduces weight."
Tirzepatide — SURMOUNT trial program
SURMOUNT-1 (2022): 2,539 participants, similar design. Mean weight reduction: 22.5% on tirzepatide 15 mg vs 2.4% on placebo at 72 weeks. 96% achieved ≥5%, 57% achieved ≥20%. SURPASS-2 (diabetes) showed superior A1c reduction vs semaglutide 1 mg. SURMOUNT-OSA (2024) showed 63% resolution of obstructive sleep apnea symptoms — comparable to surgical interventions.
Retatrutide — TRIUMPH-1 Phase 2
TRIUMPH-1 (2023, NEJM): 338 participants, doses 1, 4, 8, or 12 mg/wk for 48 weeks. Mean weight reduction: 24.2% on 12 mg vs −2.1% on placebo. Every single participant on 8 mg and 12 mg achieved ≥5% loss. 83% on 12 mg achieved ≥20% loss. A hepatic-fat substudy showed an 82.4% relative reduction in liver fat — significant for the millions of patients with NAFLD/MASLD.
The Phase 3 program (TRIUMPH-3, TRIUMPH-4, TRIUMPH-OSA) is enrolling thousands of participants. Primary completion is expected in 2025–2026, with FDA filing likely 2026 and approval anywhere from late 2026 to 2027.
Side Effects: Mostly the Same, Some Wrinkles
All three drugs share the same dominant side effect profile: gastrointestinal. Nausea, diarrhea, constipation, vomiting, and decreased appetite are dose-dependent and most common during titration. About 5–10% of patients discontinue due to GI issues.
Where retatrutide differs: glucagon agonism produces additional effects not seen with the dual or single agonists. The most consistent are a mild but persistent heart-rate elevation (3–6 bpm at maximum dose) and occasional transient elevations in liver enzymes. Both are reversible on dose reduction. Phase 3 will determine whether the cardiovascular signal is meaningful in long-term use.
All three share a black-box-equivalent warning for medullary thyroid carcinoma based on rodent studies (the actual signal in humans has not been observed but is precautionary). All three should not be used in pregnancy, in patients with a personal/family history of MTC or MEN2 syndrome, or in pancreatitis-prone patients.
Cost and Access: A Practical Calculus
| | Branded retail | Insurance | Compounding pharmacy | |---|---|---|---| | Semaglutide | $900–$1,300/mo | Often covered for T2D; weight indication varies | $200–$400/mo | | Tirzepatide | $1,000–$1,200/mo | Often covered for T2D; weight indication tightening | $250–$500/mo | | Retatrutide | n/a (not approved) | n/a | Some research-chemical channels list it; not equivalent to Lilly product |
The compounding question is changing fast. In late 2024 the FDA removed semaglutide and tirzepatide from the official shortage list, which legally restricts mass compounding of those molecules. Compounded supply continues for individualized prescriptions through 503A pharmacies but is no longer the open-pipeline it was in 2022–2024. Retatrutide compounding is in an even murkier place — the molecule is not FDA-approved, so compounding pharmacies cannot legally make it. Anything sold as "compounded retatrutide" is being sold outside the legal compounding framework. Research-chemical channels exist but offer zero verification of purity, identity, or sterility.
Who Should Consider What
This is not medical advice — talk to a prescriber who actually knows you. But here's a framework for the conversation:
Start with semaglutide if:
- You have type 2 diabetes (most insurance coverage, longest safety record)
- You have established cardiovascular disease (SELECT trial benefit)
- You want the most-studied option (>10 years of clinical data)
- Cost-sensitivity favors the older molecule
Consider tirzepatide if:
- Semaglutide hasn't produced enough weight loss
- You also have sleep apnea (SURMOUNT-OSA data)
- You can tolerate slightly more nausea during titration
Wait for retatrutide if:
- You've maxed out tirzepatide and need more loss
- You have significant liver fat (NAFLD/MASLD)
- You're already in a Phase 3 trial site
- You're willing to wait 12–24 months for legitimate access
Do not pursue retatrutide via research-chemical channels for personal use. The compounded versions sold today are not the Lilly compound used in TRIUMPH and have not been verified for what they actually contain.
The Bigger Picture
The triple agonist marks a meaningful inflection. Semaglutide and tirzepatide are excellent drugs but ultimately hit one or two of the body's metabolic signals. Retatrutide hitting three — and especially adding the energy-expenditure side — moves these compounds from "appetite suppressants" to something closer to a metabolic reset. Lilly already has a quadruple agonist (mazdutide, LY3502970) in mid-stage trials, and a retatrutide + cagrilintide combination is in development. The pipeline isn't slowing down.
For users, the practical implication: the GLP-1 you start with in 2026 probably isn't the GLP-1 you'll be on in 2028. This is a fast-moving therapeutic area. Build a relationship with a prescriber who watches it closely.
Frequently Asked Questions
Is retatrutide better than tirzepatide? On the single metric of mean weight loss in non-diabetics, yes — Phase 2 retatrutide produced 24.2% vs SURMOUNT-1 tirzepatide's 22.5%. But head-to-head trials don't exist yet, and Phase 3 retatrutide data is still pending. Tirzepatide is the most efficacious approved option in 2026.
Can I switch from semaglutide to tirzepatide (or vice versa)? Yes, but the dosing isn't 1:1 and titration should restart. Discuss with your prescriber. Some clinics use a one-week washout, others switch directly at an equivalent step.
Why is the glucagon receptor important? Glucagon agonism raises basal metabolic rate (you burn more calories at rest) and stimulates the liver to break down its own fat stores. This is the mechanism retatrutide adds that GLP-1 and GIP don't.
Is compounded retatrutide safe? There is no legally compounded retatrutide. The molecule is not FDA-approved, which means compounding pharmacies are not authorized to make it. Anything sold as "retatrutide" outside a clinical trial is operating in research-chemical territory with no quality verification.
When will retatrutide be approved? Eli Lilly has guided to a 2026 FDA filing assuming Phase 3 readouts go as expected. Approval typically follows filing by 8–14 months, putting realistic availability in late 2026 to 2027.
This article is educational and is not medical advice. Consult a licensed prescriber before starting any peptide therapy.